Kristi A. H. Elliott

Dr. Elliott joined Capricor in 2021 serving as Vice President of Research and Development where she oversees Capricor’s exosome platform and pipeline development. She has approximately 15 years of experience in biotechnology combining her extensive stem cell knowledge with over 5 years of expertise in exosome platform development. As an innovator in the exosome field, Dr. Elliott has been involved in the conception and implementation of exosome purification, scale-up, loading and targeting processes for multiple exosome-based product candidates.

Prior to her role as Vice President of Research and Development, Dr. Elliott served as a Technical Advisor in Business Development and Strategy for Exotech Bio and AD Skincare; both joint ventures between Harvest Capital Strategies and Intrexon Corp., focused on exosome therapeutics. Prior to this role, Dr. Elliott held various roles at Intrexon Corp., including Senior Director of Stem Cell and Exosome Development and Director of the Human Therapeutics Division. During her tenure at Intrexon, she managed a cross-functional team including operations, bioinformatics, engineering, and research and development. She was responsible for multiple primary and stem cell therapeutics and exosome-based research programs from concept through the development of IND-enabling studies. Dr. Elliott held several other roles in small biotechs focused on stem cell technologies and began her career as a stem cell specialist at the University of California, Irvine.

Dr. Elliott received her B.A. in biology and M.S. in molecular biology from Rutgers University. She earned her Ph.D. in human genetics and molecular biology from The Johns Hopkins School of Medicine.